Valuation: Ionis Pharmaceuticals, Inc.

Market Cap 14.27B 12.49B 11.51B 10.66B 20.25B 1,354B 20.57B 138B 53.65B 668B 53.56B 52.4B 2,310B P/E 2026 *
-24.1x
P/E 2027 * -68.4x
Enterprise Value 14.01B 12.26B 11.3B 10.48B 19.89B 1,330B 20.21B 136B 52.7B 656B 52.62B 51.48B 2,269B EV / Sales 2026 *
15.7x
EV / Sales 2027 * 9.44x
Free-Float
99.09%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Ionis Pharmaceuticals, Inc.

1 day+3.79%
1 week+8.88%
Current month+8.88%
1 month+15.91%
3 months+16.84%
6 months+3.80%
Current year+9.13%
1 week 79.11
Extreme 79.11
86.67
1 month 72.3
Extreme 72.3
86.67
Current year 68.9
Extreme 68.9
86.74
1 year 40.03
Extreme 40.03
86.74
3 years 23.95
Extreme 23.95
86.74
5 years 23.95
Extreme 23.95
86.74
10 years 23.9
Extreme 23.9
86.74
Manager TitleAgeSince
Investor Relations Contact 60 2012-06-30
Chief Executive Officer 64 2019-12-31
Director of Finance/CFO 64 2000-04-30
Director TitleAgeSince
Director/Board Member 64 2005-12-12
Director/Board Member 73 2002-04-30
Director/Board Member 64 2019-03-24
Date Insider Type Main position Quantity % Market Cap.
06-30Free

Director

7,670 0.0046%
06-30Free

Director

7,670 0.0046%
06-30Free

Chairman

7,670 0.0046%
Change 5-day change 1-year change 3-year change Capi.($)
+3.79%+8.88%+106.63%+106.63% 14.27B
-0.35%+4.58%+2.29%+8.72% 49.74B
+0.25%+1.70%+419.39%+621.71% 40.49B
-0.16%+8.42%+28.20%+63.00% 34.35B
+1.10%+7.77%+28.18%-3.96% 34.75B
+1.31%-0.56%+5.12%+33.90% 26.98B
-0.35%+0.09% - - 16.58B
-3.33%+3.15%+71.30%+131.94% 15.6B
-2.55%-1.90%+12.53%+17.95% 13.76B
-1.30%-2.87%+14.32%-28.64% 12.92B
Average -0.16%+3.50%+76.44%+105.69% 25.95B
Weighted average by Cap. +0.02%+4.21%+91.30%+131.78%

Financials

2026 *2027 *
Net sales 893M 782M 720M 668M 1.27B 84.77B 1.29B 8.64B 3.36B 41.84B 3.35B 3.28B 145B 1.5B 1.31B 1.21B 1.12B 2.13B 143B 2.17B 14.53B 5.65B 70.37B 5.64B 5.52B 243B
Net income -595M -521M -480M -445M -845M -56.51B -859M -5.76B -2.24B -27.89B -2.24B -2.19B -96.4B -199M -174M -160M -148M -282M -18.84B -286M -1.92B -747M -9.3B -745M -729M -32.15B
Net Debt -252M -221M -204M -189M -358M -23.96B -364M -2.44B -950M -11.83B -948M -927M -40.88B -88.41M -77.36M -71.3M -66.08M -125M -8.39B -127M -855M -332M -4.14B -332M -325M -14.31B
Logo Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Employees
1,402
Date Price Change Volume
26-07-07 US$86.33 +3.79% 2,646,707
26-07-06 US$83.18 +1.69% 1,847,437
26-07-02 US$81.80 +3.30% 2,301,899
26-07-01 US$79.19 -0.13% 1,442,398
26-06-30 US$79.29 -1.74% 2,380,302
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
86.33USD
Average target price
104.86USD
Spread / Average Target
+21.47%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IONS Stock